Fluoxetine and tricyclic antidepressants: Short-term tolerance of the association;Fluoxetine et antidepresseurs tricycliques: Tolerance clinique a court terme de l'association

Encephale

Volumn 22, Issue 3, 1996, Pages 221-227

  Bonin, B ^a   Bertschy, G ^b   Baumann, P ^b   Francois, T ^a   Vandel, P ^a   Vandel, S ^a   Sechter, D ^a   Bizouard, P ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

drug association; fluoxetine; side effects; tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; FLUOXETINE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG COMBINATION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; AGED; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; HOSPITAL ADMISSION; METABOLIC CLEARANCE RATE; MIDDLE AGED; PERSONALITY TEST; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PATIENT ADMISSION; PERSONALITY INVENTORY; TREATMENT OUTCOME;

EID: 0029978511     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. ARANOW RB, HUDSON JJ, HARRISON GP Jr et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989 ; 146 : 91-3.
2. BAUMANN P, BREYER-PFAFF U, KUSS HJ et al. Quality control of amitriptyline and nortriptyline plasma level assessments. A multicenter study. Pharmacopsychiatr 1982 , 15 : 156-60.
3. BAUMANN P, JONZIER-PEREY M. GC and GC-MS procedure for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 1988 ; 171 : 211-22.
4. BERTSCHY G, VANDEL S, VANDEL B et al. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding Eur J Clin Pharmacol 1991 ; 40 : 119-20.
5. BOUGEROL T. Traitement d'un épisode dépressif résistant. Encephale 1993 ; XIX : 459-66.
6. DE VANE LC. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994 ; 55 (supplt 12) : 38-45.
7. LEMOINE A, GAUTIER JC, AZOULAY D et al. Major pathway of imipramine metabolism is catalysed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Molecular Pharmacology 1993 ; 43 : 827-32.
8. LINGJAERDE O, AHLFORS UG, BECH P et al. The UKU side effect rating scale. Acta Psychiatr Scand 1987 ; 76 (supplt 334) : 100.
9. MONTGOMERY SA, ASBERG MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 ; 134 . 382-9.
10. NELSON J, MAZURE CM, BOWERS MB et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression Arch Gen Psychiatry 1991 ; 48 : 303-7.
11. PRESKORN SH, BEBER JH, FAULJC et al. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 1990 ; 147 : 532.
12. SETH R, JENNINGS A, BINDMAN J et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992 , 161 : 562-5.
13. VANDEL B, VANDEL S, JOUNET JM et al. Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response. Eur J Clin Pharmacol 1982 ; 22 : 15-20.
14. VANDEL S, BERTSCHY G, BONIN B et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiol 1992 ; 25 : 202-7.
15. VAUGHAN DA. Interaction of fluoxetine with tricyclic antidepressant. Am J Psychiatry 1988 ; 145 : 1478.
16. WEILBURG JB, ROSENBAUM JF, BIEDERMAN J et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders : a preliminary report. J Clin Psychiatry 1989 , 50 : 477-8.